An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of the ILDR2 Function-blocking Antibody BAY1905254 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2019
At a glance
- Drugs BAY 1905254 (Primary)
- Indications Cervical cancer; Head and neck cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Bayer
- 10 Jan 2019 Planned End Date changed from 30 Nov 2021 to 14 Jul 2023.
- 10 Jan 2019 Planned primary completion date changed from 30 Nov 2021 to 14 Jul 2023.
- 20 Sep 2018 According to a Compugen media release, Bayer AG dosed the first patient in this trial.